Monoclonal human IgG4 antibody against human CD20

Anti-hCD20-hIgG4 features the constant region of the human IgG4 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia. Anti-hCD20-hIgG4 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.



Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgG4


100 µg purified anti-hCD20-hIgG4 antibody, provided azide-free and lyophilized


Recent articles using InvivoGen Anti-hCD20-hIgG4



Cat. Codehcd20-mab4
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".